Theromics

Theromics, founded with a mission to enhance the effectiveness of thermal ablation procedures, focuses on developing innovative medical technologies to improve patient outcomes. Their flagship product, HeatSYNC™ TA, is a biopolymer gel designed to amplify heat energy movement during microwave and radiofrequency ablations of cancerous tumors. This gel, made from naturally occurring proteins, can be delivered via syringe, laparoscope, or bronchoscope, aiming to create more effective ablation zones in soft tissue and bone.

Theromics has garnered attention for its pioneering approach to thermal ablation, attracting notable investors and medical professionals committed to advancing cancer treatment technologies. The company’s HeatSYNC™ gel has shown promise in increasing the precision and efficiency of tumor ablations, potentially reducing costs and improving patient care. As a result, Theromics is poised to make a significant impact on the medical field by offering a more focused and patient-centric solution for thermal ablation procedures.